What sector does RaQualia Pharma Inc. belong to?

RaQualia Pharma Inc. operates in the Pharmaceuticals sector, specifically the Pharmaceutical industry, and is listed on the US markets.

What is the current share price of 4579?

As of the latest available quote, 4579 traded at ¥542.00. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of 4579?

RaQualia Pharma Inc. has a price-to-earnings (P/E) ratio of about 62.08. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of 4579?

The market capitalisation of RaQualia Pharma Inc. is approximately ¥12.84B.

Does 4579 pay a dividend?

RaQualia Pharma Inc. does not currently show a dividend yield in our data.

What is the return on equity (ROE) of 4579?

RaQualia Pharma Inc. has a return on equity (ROE) of about 4.40%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of 4579?

Over the past 52 weeks, 4579 has traded between a low of ¥438.00 and a high of ¥1,465.00.

RaQualia Pharma Inc.

4579 TSE Pharmaceuticals Pharmaceutical

TSE Growth

¥542.00

-1.99%

Delayed · cached 15 min

Fair value analysis

4579

RaQualia Pharma Inc.

¥542.00

Close used for this calculation

¥218.22Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

29/100

Profitability14/25

Returns1/25

Balance Sheet10/25

Efficiency4/25

Growth12/25

Weak

Quality radar

Consensus fair value

¥218.22

Above FV

▼ -59.7% against the close used

Model range ¥55.88 – ¥269.22

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear¥55.88Fair value¥218.22Bull¥269.22

FairClose

52-week traded range

52W low ¥453.0052W high ¥1,429.00

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading above the consensus fair value

RaQualia Pharma Inc. closed at ¥542.00, 148.4% above the consensus fair value of ¥218.22 drawn from 8 valuation models.

Financial DNA score 29/100 — Weak. P/E of 47.0x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

¥216.10

-60.1%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=8%, r=10%, tg=3%, n=10yr

Graham Number

¥269.22

-50.3%

√(22.5 × EPS × BVPS)

EPS=11.53, BVPS=279.38 · outside Graham range (P/E 47, P/B 1.9) — asset-light, treat as a rough floor

P/E Fair Value

¥230.60

-57.5%

EPS × 20x (sector P/E)

EPS=11.53, Sector P/E=20x

Peter Lynch (PEG)

¥259.08

-52.2%

EPS × Growth% (PEG = 1 is fair)

EPS=11.53, g=22.5%

EV/EBITDA

¥199.58

-63.2%

(EBITDA × 10x − Net Debt) ÷ Shares

EBITDA=686.63M

Book Value (P/B)

¥55.88

-89.7%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=279.38, ROE=4.4%, g=3%, r=10%

Reverse DCF

¥542.00

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 18.7% | Historical: -22.5%

Margin of Safety

¥178.98

-67.0%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=238.64, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer